Platelet-activating factor-acetylhydrolase (PAF-AH) activity in pulmonary arterial hypertension (PAH) Source: Eur Respir J 2005; 26: Suppl. 49, 695s Year: 2005
C-reactive protein and platelet-activating factor-acetylhydrolase activity: new predictors of outcome in pulmonary hypertension Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases Year: 2008
The role of thrombophilic risk factors in the severity of pulmonary thromboembolism Source: Eur Respir J 2002; 19: 709-711 Year: 2002
Effects of platelet-activating factor (PAF) challenge on airway neutrophilia and adhesion molecules in mild asthma Source: Eur Respir J 2001; 18: Suppl. 33, 163s Year: 2001
Regulation of inflammation process in chronic thromboembolic pulmonary hypertension: a potential role of platelet-activating factor-acetylhydrolase Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006
The importance of high plasma levels of factor VIIIc in the severity of pulmonary thromboembolism Source: Eur Respir J 2001; 18: Suppl. 33, 252s Year: 2001
Elevated factor FVIII:C levels in patients with pulmonary hypertension: a marked of endothelial dysfunction? Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003
Expression of platelet derived-growth factor (PDGF) in remodelled pulmonary arteries of COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 25s Year: 2002
Recovery of neutrophil apoptosis by ectoine: a new strategy against lung inflammation Source: Eur Respir J 2013; 41: 433-442 Year: 2013
Elevated Von Willebrand Factor expression in the activated pulmonary endothelium of chronic thromboembolic pulmonary hypertension patients enhances platelet adhesion. Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020
Impact of recombinant factor VIIa (rFVIIa) on transfusion related acute lung injury (TRALI) Source: Eur Respir J 2006; 28: Suppl. 50, 180s Year: 2006
Response of plasma von Willebrand factor to systemic endothelial injury in pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 545s Year: 2006
Dual mechanism of platelet-derived growth factor (PDGF)-receptor: Contribution of vascular response to the pathogenesis of pulmonary hypertension (PH) Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015
The Factor V Leiden variant and risk of chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 56 (4) 2000774; 10.1183/13993003.00774-2020 Year: 2020
Arterial concentration of macrophage migration inhibitory factor (MIF) increases with exercise in patients with pulmonary hypertension (PH) Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010
Macrophage migration inhibitory factor (MIF ) promoter polymorphisms are associated with favorable hemodynamic indices in systemic sclerosis-associated pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology Year: 2012
Platelet-activating factor reduces endothelial nitric oxide production: role of acid sphingomyelinase Source: Eur Respir J 2010; 36: 417 Year: 2010
Fibrinogen Aα Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2008; 31: 736-741 Year: 2008
C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary circulation Year: 2009
Hypercoagulability in patients with stable COPD assessed by coagulation factor levels Source: Virtual Congress 2020 – Epidemiology, diagnosis and management of pulmonary embolism Year: 2020